Jacobs Levy Equity Management, Inc Replimune Group, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Replimune Group, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 39,521 shares of REPL stock, worth $505,473. This represents 0.0% of its overall portfolio holdings.
Number of Shares
39,521
Previous 83,674
52.77%
Holding current value
$505,473
Previous $753,000
42.5%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding REPL
# of Institutions
149Shares Held
68MCall Options Held
52.3KPut Options Held
80.3K-
Baker Bros. Advisors LP New York, NY11MShares$141 Million1.3% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD9.88MShares$126 Million0.01% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.87MShares$62.2 Million9.16% of portfolio
-
Redmile Group, LLC San Francisco, CA4.78MShares$61.2 Million3.43% of portfolio
-
Black Rock Inc. New York, NY4.71MShares$60.3 Million0.0% of portfolio
About Replimune Group, Inc.
- Ticker REPL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,306,700
- Market Cap $631M
- Description
- Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...